Compare Crispr Therapeutics AG (CRSP) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Phillips 66 — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Phillips 66 trades at $278.18 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 23× Crispr Therapeutics AG's market cap, and Phillips 66 pays a 1.8% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Phillips 66 for 62 Days on average.
| CRSP | PSX | |
|---|---|---|
Market Cap | $4.88B | $112.36B |
Volume | 2,861,747 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $73.97 | $281.60 |
52-Week Low | $44.34 | $126.76 |
Typical Hold Time | 77 Days | 62 Days |
Enterprise Value | $3.30B | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Phillips 66 (PSX) trades at $281.60, up 3.67% with strong technical momentum as it approaches resistance at $284. The stock shows robust fundamentals with three consecutive earnings beats and improving cash flow projections for 2026. Recent news highlights structural refining advantages and AI implementation for operational efficiency, supporting the bullish analyst consensus.
PSX offers attractive valuation with P/E of 16.07 and P/S of 0.75, coupled with strong profitability metrics including 24.02% ROE. Key risks include commodity price volatility and potential policy impacts on diesel exports. With 54% analyst buy ratings and $279 consensus target, the stock presents growth potential despite near-term overbought technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
